bilastine (BioDeep_00000858716)

   


代谢物信息卡片


bilastine

化学式: C28H37N3O3 (463.2834772)
中文名称: 比拉斯汀
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC(C)(C1=CC=C(CCN2CCC(C3=NC4=CC=CC=C4N3CCOCC)CC2)C=C1)C(O)=O
InChI: InChI=1S/C28H37N3O3/c1-4-34-20-19-31-25-8-6-5-7-24(25)29-26(31)22-14-17-30(18-15-22)16-13-21-9-11-23(12-10-21)28(2,3)27(32)33/h5-12,22H,4,13-20H2,1-3H3,(H,32,33)

描述信息

R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use
S - Sensory organs > S01 - Ophthalmologicals > S01G - Decongestants and antiallergics
C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist
Bilastine is a histamine H1 receptor antagonist that can be used to treat allergic rhinoconjunctivitis and urticaria.

同义名列表

1 个代谢物同义名

bilastine



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • Aya Saad Radwan, Mahmoud M Elkhoudary, Ghada M Hadad, Fathalla Belal, Mohamed M Salim. A highly sensitive spectrofluorimetric method for the determination of bilastine in its pharmaceutical preparations and biological fluids. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy. 2022 Aug; 276(?):121246. doi: 10.1016/j.saa.2022.121246. [PMID: 35429867]
  • Dolores Ochoa, Manuel Román, Carmen Belmonte, Samuel Martín-Vilchez, Gina Mejía-Abril, Francisco Abad-Santos, Gonzalo Hernández, Paula Arranz, Lorena Elgezabal, Nieves Fernández. Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation. Advances in therapy. 2021 07; 38(7):4070-4081. doi: 10.1007/s12325-021-01801-y. [PMID: 34125400]
  • Áurea Redondo-Sendino, Isabel Cristina González Sánchez, Beatriz de Victoria Fernández. [Skin manifestations associated with the new coronavirus SARS-CoV-2 disease]. Medicina clinica. 2020 11; 155(9):414-415. doi: 10.1016/j.medcli.2020.04.057. [PMID: 32873395]
  • Mónica Rodríguez, Valvanera Vozmediano, Aintzane García-Bea, Zoltán Novák, Anahí Yáñez, Cristina Campo, Luis Labeaga. Pharmacokinetics and safety of bilastine in children aged 6 to 11 years with allergic rhinoconjunctivitis or chronic urticaria. European journal of pediatrics. 2020 May; 179(5):801-805. doi: 10.1007/s00431-019-03559-6. [PMID: 31919579]
  • Belén Sádaba, Jose Ramón Azanza, Aintzane García-Bea, Luis Labeaga, Cristina Campo, Román Valiente. Bioequivalence Evaluation of Three Pediatric Oral Formulations of Bilastine in Healthy Subjects: Results from a Randomized, Open Label, Crossover Study. European journal of drug metabolism and pharmacokinetics. 2020 Apr; 45(2):265-272. doi: 10.1007/s13318-019-00596-2. [PMID: 31820304]
  • Roberta Verta, Cristina Grange, Maura Gurrieri, Sara Borga, Patrizia Nardini, Monica Argenziano, Corrado Ghè, Roberta Cavalli, Elisa Benetti, Gianluca Miglio, Benedetta Bussolati, Alessandro Pini, Arianna Carolina Rosa. Effect of Bilastine on Diabetic Nephropathy in DBA2/J Mice. International journal of molecular sciences. 2019 May; 20(10):. doi: 10.3390/ijms20102554. [PMID: 31137660]
  • Valvanera Vozmediano, Ander Sologuren, John C Lukas, Nerea Leal, Mónica Rodriguez. Model Informed Pediatric Development Applied to Bilastine: Ontogenic PK Model Development, Dose Selection for First Time in Children and PK Study Design. Pharmaceutical research. 2017 Dec; 34(12):2720-2734. doi: 10.1007/s11095-017-2248-6. [PMID: 28971281]
  • Michinori Togawa, Hidetoshi Yamaya, Mónica Rodríguez, Hirotaka Nagashima. Pharmacokinetics, Pharmacodynamics and Population Pharmacokinetic/Pharmacodynamic Modelling of Bilastine, a Second-Generation Antihistamine, in Healthy Japanese Subjects. Clinical drug investigation. 2016 Dec; 36(12):1011-1021. doi: 10.1007/s40261-016-0447-2. [PMID: 27498100]
  • Magí Farré, Clara Pérez-Mañá, Esther Papaseit, Esther Menoyo, Marta Pérez, Soraya Martin, Santiago Bullich, Santiago Rojas, José-Raúl Herance, Carlos Trampal, Luis Labeaga, Román Valiente. Bilastine vs. hydroxyzine: occupation of brain histamine H1 -receptors evaluated by positron emission tomography in healthy volunteers. British journal of clinical pharmacology. 2014 Nov; 78(5):970-80. doi: 10.1111/bcp.12421. [PMID: 24833043]
  • Valvanera Vozmediano, Ignacio Ortega, John C Lukas, Ana Gonzalo, Monica Rodriguez, Maria Luisa Lucero. Integration of preclinical and clinical knowledge to predict intravenous PK in human: bilastine case study. European journal of drug metabolism and pharmacokinetics. 2014 Mar; 39(1):33-41. doi: 10.1007/s13318-013-0131-3. [PMID: 23619917]
  • Kenneth C Lasseter, Ander Sologuren, Anna La Noce, Stacy C Dilzer. Evaluation of the single-dose pharmacokinetics of bilastine in subjects with various degrees of renal insufficiency. Clinical drug investigation. 2013 Sep; 33(9):665-73. doi: 10.1007/s40261-013-0110-0. [PMID: 23873362]
  • B Sádaba, A Gómez-Guiu, J R Azanza, I Ortega, R Valiente. Oral availability of bilastine. Clinical drug investigation. 2013 May; 33(5):375-81. doi: 10.1007/s40261-013-0076-y. [PMID: 23529786]
  • Benoît Tyl, Meriam Kabbaj, Sara Azzam, Ander Sologuren, Román Valiente, Elizabeth Reinbolt, Kathryn Roupe, Nathalie Blanco, William Wheeler. Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysis. Journal of clinical pharmacology. 2012 Jun; 52(6):893-903. doi: 10.1177/0091270011407191. [PMID: 21642470]
  • María Luisa Lucero, Andrew B Patterson. Whole-body tissue distribution of total radioactivity in rats after oral administration of [¹⁴C]-bilastine. Drug and chemical toxicology. 2012 Jun; 35 Suppl 1(?):1-7. doi: 10.3109/01480545.2012.682650. [PMID: 22616810]
  • Claus Graff, Johannes J Struijk, Jørgen K Kanters, Mads P Andersen, Egon Toft, Benoît Tyl. Effects of bilastine on T-wave morphology and the QTc interval: a randomized, double-blind, placebo-controlled, thorough QTc study. Clinical drug investigation. 2012 May; 32(5):339-51. doi: 10.2165/11599270-000000000-00000. [PMID: 22393898]
  • Nerea Jauregizar, Leire de la Fuente, Maria Luisa Lucero, Ander Sologuren, Nerea Leal, Mónica Rodríguez. Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine. Clinical pharmacokinetics. 2009; 48(8):543-54. doi: 10.2165/11317180-000000000-00000. [PMID: 19705924]
  • Reyes Corcóstegui, Luis Labeaga, Ana Innerárity, Agustin Berisa, Aurelio Orjales. Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs in R&D. 2005; 6(6):371-84. doi: 10.2165/00126839-200506060-00005. [PMID: 16274260]
  • L A Berrueta, M Fernández-Armentia, A Bakkali, A Gonzalo, M L Lucero, A Orjales. Matrix solid-phase dispersion technique for the determination of a new antiallergic drug, bilastine, in rat faeces. Journal of chromatography. B, Biomedical sciences and applications. 2001 Aug; 760(1):185-90. doi: 10.1016/s0378-4347(01)00267-5. [PMID: 11522062]